



## Ramucirumab 8 / Paclitaxel 80, adenocarcinoma esophagogastric junction and stomach

Protocol-ID: 327 V1.2 (Basic), RAMU8/PACL80, AEG/Gastric Ca

### Indication(s)

- Gastric Cancer; ICD-10 C16.-, C16.0
- Esophageal Cancer (Adenocarcinoma of the esophagogastric junction (AEG)); ICD-10 C15.-

### Cycles

Cycle length 28 days, recommended cycles: 5

### Protocol sequences

- [ARMANI: CAPOX \(CAPE1000/OXAL130\), AEG/Gastric Ca \(PID2933\) or mFOLFOX-6 \(OXAL85/CFOL400/FU2400\), AEG/Gastric Ca \(PID2939\) -|- RAMU8/PACL80, AEG/Gastric Ca \(PID327\)](#)

### References

- Wilke H, Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol* 2014 Oct;15(11):1224-35. doi: 10.1016/S1470-2045(14)70420-6. PMID: 25240821. [[PMID](#)]
- Randon G, Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol* 2024 Dec;25(12):1539-1550. doi: 10.1016/S1470-2045(24)00580-1. PMID: 39557058. [[PMID](#)]

### Recommendations

- 09/2016: [European Society for Medical Oncology](#)
- 06/2021: [National Comprehensive Cancer Network](#)

### Important notice

The copyrighted protocols are treatment recommendations. The information contained in this compilation on cytostatic drugs, concomitant medication and other therapeutic procedures, as well as dosage and application information, is continuously reviewed with all due care by the authors and editors involved. Nevertheless, the publishers and authors do not assume any liability for the correctness - also with regard to possible printing errors.

The protocols may not be changed in terms of content.

Diagnosis, indication for therapy and treatment of malignant diseases must be carried out in each individual case by the hematologist and oncologist on his or her own responsibility. The treating physician is obligated to this personal responsibility to weigh in each case before a diagnostic or therapeutic measure, indication, contraindications, dosage and application under consideration of the specialized information or other documents of the manufacturers. This applies in particular to rarely used preparations or preparations that are new to the market.



The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 04.07.2021